{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:54:45Z","timestamp":1783727685803,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jaad.2020.08.127","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T22:12:19Z","timestamp":1600207939000},"page":"1000-1009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry"],"prefix":"10.1016","volume":"84","author":[{"given":"Lieneke F.M.","family":"Ari\u00ebns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorien","family":"van der Schaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte S.","family":"Spekhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne S.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruida L.E.","family":"Romeijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa A.","family":"Kouwenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Kamsteeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique N.","family":"Voorberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Oosting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Sloeserwij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Haeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith L.","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie L.A.","family":"Schuttelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein S.","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10086","key":"10.1016\/j.jaad.2020.08.127_bib1","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.127_bib2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"24","key":"10.1016\/j.jaad.2020.08.127_bib3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.127_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.127_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.127_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.127_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjd.18179","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data","volume":"182","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.127_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry","volume":"75","author":"Ariens","year":"2020","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.127_bib9","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.jaad.2020.02.029","article-title":"Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: a retrospective cohort study","volume":"82","author":"Jo","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.127_bib10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2020.05.128","article-title":"Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (Treatment of Atopic Eczema, The Netherlands) registry","volume":"83","author":"Bosma","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.08.127_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.127_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/intimm\/11.1.81","article-title":"Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine","volume":"11","author":"Imai","year":"1999","journal-title":"Int Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.127_bib13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.08.127_bib14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective","volume":"140","author":"Charman","year":"2004","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.127_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2020.08.127_bib16","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s11136-020-02499-1","article-title":"Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study","volume":"29","author":"Vilsboll","year":"2020","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.jaad.2020.08.127_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.14050","article-title":"Acute arthritis and arthralgia as an adverse drug reaction to dupilumab","volume":"45","author":"de Wijs","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.127_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bjd.14398","article-title":"Drug survival for azathioprine and enteric-coated mycophenolate sodium in a long-term daily practice cohort of adult patients with atopic dermatitis","volume":"175","author":"van der Schaft","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.08.127_bib19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/bjd.13730","article-title":"Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis","volume":"172","author":"van der Schaft","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.127_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bjd.13961","article-title":"Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis","volume":"174","author":"Politiek","year":"2016","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2020.08.127_bib21","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2020.08.127_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.08.127_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaip.2018.10.009","article-title":"Atopic dermatitis is associated with increased prevalence of multiple ocular comorbidities","volume":"7","author":"Govind","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.127_bib24","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.127_bib25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jaad.2020.08.127_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther"},{"issue":"26","key":"10.1016\/j.jaad.2020.08.127_bib27","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2020.08.127_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220326189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220326189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:58:56Z","timestamp":1759273136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220326189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0190962220326189"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.127","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}